In treated group II, QC administration significantly increased brain SOD and GSH while decreasing the oxidation parameters (MDA and AOPP) compared to the AD group, whereas all these values were significantly changed compared to the control group. The gene discussed is SOD1; the disease is Alzheimer disease.